Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | LTA4H | P09960 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | AGXT | P21549 | 1/20 | 0.41 |
| ▸ | NAAA | Q02083 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4153126 | 0.81 | MAOA (0.55) | MAOAMAOBTSHRIDO1TACR1 | |
| SCHEMBL30959761 | 0.79 | TSHR (0.47) | MAOAMAOBTSHRALDH1A1IDO1 | |
| SCHEMBL25237906 | 0.79 | TSHR (0.47) | TSHRALDH1A1IDO1TACR1LTA4H | |
| SCHEMBL4750397 | 0.79 | TSHR (0.47) | MAOAMAOBTSHRALDH1A1IDO1 | |
| SCHEMBL21439103 | 0.78 | TSHR (0.50) | TSHRALDH1A1IDO1TACR1LTA4H | |
| SCHEMBL13571223 | 0.76 | TACR1 (0.55) | MAOAMAOBTSHRALDH1A1TACR1 | |
| SCHEMBL21835425 | 0.75 | TSHR (0.47) | TSHRALDH1A1TACR1LTA4HCHRM3 | |
| SCHEMBL22437368 | 0.75 | TSHR (0.47) | TSHRALDH1A1CHRM3CHRM2CHRM1 | |
| SCHEMBL4977065 | 0.75 | CA2 (0.46) | TSHRALDH1A1TACR1LTA4HCHRM3 | |
| SCHEMBL4161505 | 0.75 | ALDH1A1 (0.43) | TSHRALDH1A1CHRM3CHRM2CHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-RE49481-E1 | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | HOFFMANN-LA ROCHE INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2022-11-17 | — | — | US | disclosed |
| CN-113382986-A | Tyrosine kinase inhibitor compositions, methods of making and methods of using the same | 黑钻治疗公司 | 2021-09-10 | — | — | CN | disclosed |
| EP-3856726-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE | Black Diamond Therapeutics, Inc. (US) | 2021-08-04 | — | — | EP | disclosed |
| US-11034672-B1 | Tyrosine kinase inhibitor compositions, methods of making and methods of use | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2021-06-15 | — | — | US | disclosed |
| US-20210163447-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | BLACK DIAMOND THERAPEUTICS, INC. | 2021-06-03 | — | — | US | disclosed |
| WO-2020068867-A1 | QUINAZOLINE DERIVATIVES AS TYROSINE KINASE INHIBITOR, COMPOSITIONS, METHODS OF MAKING THEM AND THEIR USE | BLACK DIAMOND THERAPEUTICS, INC. (US) | 2020-04-02 | — | — | WO | disclosed |
| EP-2881384-B1 | PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAISHO PHARMACEUTICAL CO LTD (JP) | 2018-05-30 | — | — | EP | disclosed |
| US-9422240-B2 | Partially saturated nitrogen-containing heterocyclic compound | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-08-23 | — | — | US | disclosed |
| US-7294632-B2 | Substituted 8′-pyridinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a]pyrimidin-6-one and 8′-pyrimidinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a]pyrimidin-6-one derivatives | SANOFI-AVENTIS (FR) | 2007-11-13 | — | — | US | disclosed |
| US-20060025431-A1 | Substituted 8'-pyridinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a]pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a]pyrimidin-6-one derivatives | SANOFI-AVENTIS (FR) | 2006-02-02 | — | — | US | disclosed |
| EP-1603915-A1 | SUBSTITUTED 8 -PYRIDINYL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE AND 8 -PYRIMIDIN YL-DIHYDROSPIRO- CYCLOALKYL -PYRIMIDO 1,2-a PYRIMIDIN-6-ONE DERIVATIVES AND THEIR USE AGAINST NEUROGENERATIVE DISEASES | Sanofi-Aventis (FR) | 2005-12-14 | — | — | EP | disclosed |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-11-24 | — | — | US | disclosed |
| US-20050208582-A1 | Pyrazole compounds and pharmaceutical compositions comprising the compound | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-09-22 | — | — | US | disclosed |
| CN-1656079-A | Pyrazole compounds and pharmaceutical compositions containing the same | EISAI CO LTD (JP) | 2005-08-17 | — | — | CN | disclosed |
| EP-1510516-A1 | PYRAZOLE COMPOUND AND MEDICINAL COMPOSITION CONTAINING THE SAME | Eisai Co., Ltd. (JP) | 2005-03-02 | — | — | EP | disclosed |
| WO-2004078760-A1 | SUBSTITUTED 8'-PYRIDINYL-DIHYDROSPIRO-[CYCLOALKYL]-PYRIMIDO [1,2-a] PYRIMIDIN-6-ONE AND 8'-PYRIMIDINYL-DIHYDROSPIRO-[CYCLOALKYL]-PYRIMIDO [1,2-a] PYRIMIDIN-6-ONE DERIVATIVES AND THEIR USE AGAINST NEUROGENERATIVE DISEASES | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | WO | disclosed |
| EP-1454909-A1 | Substituted 8'-pyridinyl-dihydrospiro-(cycloalkyl)-pyrimido(1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro-(cycloalkyl)-pyrimido(1,2-a)pyrimidin-6-one derivatives and their use against neurodegenerative diseases | SANOFI-SYNTHELABO (FR) | 2004-09-08 | — | — | EP | disclosed |
| EP-1454909-A1 | Substituted 8'-pyridinyl-dihydrospiro-(cycloalkyl)-pyrimido(1,2-a) pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro-(cycloalkyl)-pyrimido(1,2-a)pyrimidin-6-one derivatives and their use against neurodegenerative diseases | SANOFI-SYNTHELABO (FR) | 2004-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11034672-B1 | Tyrosine kinase inhibitor compositions, methods of making and methods of use | ERBB2, ERBB3, EGFR | MAOA 1813/4885MAOB 1185/4885TSHR 971/4885 |
| US-20050261339-A1 | Pyrazole compound and medicinal composition containing the same | CNKSR1, NR3C2, CSNK2B | MAOA 2624/4885MAOB 2177/4885TSHR 992/4885 |
| US-20060025431-A1 | Substituted 8'-pyridinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a]pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro-[cycloalkyl]-pyrimido[1,2-a]pyrimidin-6-one derivatives | PSEN1, PSEN2, GSK3A | MAOA 169/4885MAOB 566/4885TSHR 4227/4885 |
| US-20220363666-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | MAOA 1813/4885MAOB 1185/4885TSHR 971/4885 |
| US-20210163447-A1 | TYROSINE KINASE INHIBITOR COMPOSITIONS, METHODS OF MAKING AND METHODS OF USE | ERBB2, ERBB3, EGFR | MAOA 1813/4885MAOB 1185/4885TSHR 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.